Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.
N/A
65 Years
N/A
65 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.
Inclusion Criteria:
- Adult patients, > 65 years of age
- Locally advanced or metastatic non-small cell lung cancer (Stage IIIb or IV)
- Failure of at least one prior standard platinum-based chemotherapy
Exclusion Criteria:
- Age < 65 years
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall survival according to different age groups
Outcome Time Frame:
at 1 year
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
ML23023
NCT ID:
NCT01535729
Start Date:
May 2011
Completion Date:
May 2015
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
